Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
by Zacks Equity Research
Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $264 in the latest trading session, marking a -0.52% move from the prior day.
Vertex Eyes Label Expansion of Triple Combo CF Drug in Europe
by Zacks Equity Research
Vertex's (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $257.96 in the latest trading session, marking a +0.9% move from the prior day.
CRISPR Stocks: Buy or Trade?
by Kevin Cook
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
J&J to Stop Development of Influenza Candidate Pimodivir
by Zacks Equity Research
Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.
Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations
by Zacks Equity Research
Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.
AstraZeneca's Farxiga Betters Survival in Renal Outcome Study
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga significantly reduces the risk of kidney failure and cardiovascular or death in patients with chronic kidney disease.
Why Is Vertex (VRTX) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Biotech Industry Near-Term Outlook Modest Amid Coronavirus
by Zacks Equity Research
With the coronavirus outbreak refusing to subside anytime soon, biotech companies gain focus as they race against time to evaluate every possible therapy to break the chain.
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod
by Zacks Equity Research
Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.
The Zacks Analyst Blog Highlights: Amazon, Amgen, TOTAL, Vertex Pharmaceuticals and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Amgen, TOTAL, Vertex Pharmaceuticals and FedEx
Top Research Reports for Amazon, Amgen & TOTAL
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Amgen (AMGN) and TOTAL (TOT).
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
by Zacks Equity Research
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More
by Kinjel Shah
Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.
Top Stock Reports for AstraZeneca, Union Pacific & Altria
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca (AZN), Union Pacific (UNP) and Altria Group (MO).
Why Vertex (VRTX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.